TRCT
MLTX icon

Tower Research Capital (TRC)’s MoonLake Immunotherapeutics MLTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-704
Closed -$9.28K – 5386
2025
Q4 		$9.28K Buy
704
+703
+70,300% +$8.29K ﹤0.01% 3909
2025
Q3 		$7 Sell
1
-273
-100% -$14.2K ﹤0.01% 5182
2025
Q2 		$12.9K Buy
274
+128
+88% +$5.21K ﹤0.01% 3880
2025
Q1 		$5.7K Buy
+146
New +$6.29K ﹤0.01% 4093
2024
Q4 		– Sell
-1,672
Closed -$84.3K – 5885
2024
Q3 		$84.3K Buy
1,672
+1,625
+3,457% +$76.1K ﹤0.01% 2353
2024
Q2 		$2.07K Sell
47
-232
-83% -$9.83K ﹤0.01% 5057
2024
Q1 		$14K Buy
279
+214
+329% +$11.6K ﹤0.01% 3346
2023
Q4 		$3.92K Sell
65
-127
-66% -$6.54K ﹤0.01% 5025
2023
Q3 		$10.9K Sell
192
-720
-79% -$39.7K ﹤0.01% 4058
2023
Q2 		$46.5K Buy
+912
New +$24.5K ﹤0.01% 2644
2022
Q3 		– Sell
-25
Closed – – 6323
2022
Q2 		$0 Buy
+25
New +$157 ﹤0.01% 6353
2022
Q1 		– Sell
-193
Closed -$2K – 6376
2021
Q4 		$2K Buy
193
+76
+65% +$755 ﹤0.01% 5638
2021
Q3 		$1K Buy
117
+100
+588% +$998 ﹤0.01% 5503
2021
Q2 		$0 Buy
+17
New +$173 ﹤0.01% 5696
2021
Q1 		– Sell
-7
Closed – – 5586
2020
Q4 		$0 Buy
+7
New +$74 ﹤0.01% 5307

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Tower Research Capital (TRC)'s MLTX Position: Q1 2026 in Review

Tower Research Capital (TRC) sold out of MoonLake Immunotherapeutics (MLTX) in Q1 2026, closing a stake of 704 shares — an estimated $9.28K sold.

Tower Research Capital (TRC) first reported a position in MLTX in Q4 2020 and held it in 15 quarters. The position peaked at $84.3K in Q3 2024. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Tower Research Capital (TRC) reported no remaining MoonLake Immunotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 704 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $9.28K.
  • Tower Research Capital (TRC) first reported a position in MoonLake Immunotherapeutics in Q4 2020 and held it in 15 quarters.
  • Tower Research Capital (TRC)'s MoonLake Immunotherapeutics position peaked at $84.3K in Q3 2024.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.